 |
18 Diseases |  |
32 Trials |
|
32 Trials |  |
839 News |  |
| «12...45678910111213141516» |
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
New P2 trial: SPLENEVAC-2: Revaccination With PPS23 Boosted or Not by PCV13 in Splenectomised Patients. (clinicaltrials.gov) - Mar 13, 2019
P2, N=56, Not yet recruiting, Sponsor: Assistance Publique - H
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Trial primary completion date, Pneumococcal vaccines: Pneumococcal Vaccines in Patients With Asthma (clinicaltrials.gov) - Mar 5, 2019
P4, N=50, Recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Dec 2018 --> Dec 2019
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Enrollment closed, Trial completion date, Trial primary completion date, Pneumococcal vaccines: Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines (clinicaltrials.gov) - Feb 26, 2019
P=N/A, N=40, Active, not recruiting, Sponsor: The Jackson Laboratory
Trial primary completion date: Dec 2018 --> Dec 2019 Recruiting --> Active, not recruiting | Trial completion date: Apr 2021 --> Apr 2020 | Trial primary completion date: Apr 2021 --> Dec 2019
- |||| GSK5101955 / GSK
Enrollment open, Pneumococcal vaccines: A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine (clinicaltrials.gov) - Feb 25, 2019
P1/2, N=618, Recruiting, Sponsor: Astellas Pharma Global Development, Inc.
Recruiting --> Active, not recruiting | Trial completion date: Apr 2021 --> Apr 2020 | Trial primary completion date: Apr 2021 --> Dec 2019 Not yet recruiting --> Recruiting
- ||||| methotrexate / Generic mfg.
Enrollment closed: VACIMRA: VACcination In Methotrexate Treated Rheumatoid Arthritis Patients (clinicaltrials.gov) - Feb 4, 2019
P3, N=276, Active, not recruiting, Sponsor: University Hospital, Montpellier
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
New P1 trial, Pneumococcal vaccines: Pneumococcal Conjugate Vaccine in Aging Renal Transplant (clinicaltrials.gov) - Jan 14, 2019
P1, N=275, Recruiting, Sponsor: VA Office of Research and Development
- ||||| GSK5101955 / GSK
New P1/2 trial, Pneumococcal vaccines: A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine (clinicaltrials.gov) - Jan 13, 2019
P1/2, N=618, Not yet recruiting, Sponsor: Astellas Pharma Global Development, Inc.
- |||||| Prevnar 20 (pneumococcal 20-valent conjugate vaccine) / Pfizer
Enrollment open, Pneumococcal vaccines: Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-na (clinicaltrials.gov) - Dec 19, 2018
P3, N=3880, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
New P4 trial: IPS-BOOSTER: Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease (clinicaltrials.gov) - Dec 4, 2018
P4, N=300, Active, not recruiting, Sponsor: Region Skane
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
Enrollment closed: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX (clinicaltrials.gov) - Nov 30, 2018
P3, N=600, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Prevnar 20 (pneumococcal 20-valent conjugate vaccine) / Pfizer
New P3 trial, Pneumococcal vaccines: Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-na (clinicaltrials.gov) - Nov 30, 2018
P3, N=3880, Not yet recruiting, Sponsor: Pfizer
- | Rabavert (purified chicken-embryo cell rabies vaccine) / Bavarian Nordic
Enrollment status, Enrollment change: Antibody Production in Immune Disorders (clinicaltrials.gov) - Nov 27, 2018
P=N/A, N=21, Enrolling by invitation, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Recruiting --> Enrolling by invitation | N=50 --> 21
- | Enrollment closed, Trial completion date, Trial primary completion date: Vaccinating Children After Chemotherapy (clinicaltrials.gov) - Nov 6, 2018
P4, N=154, Active, not recruiting, Sponsor: Canadian Immunization Research Network
Recruiting --> Enrolling by invitation | N=50 --> 21 Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Mar 2019 | Trial primary completion date: Dec 2018 --> Mar 2019
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), NN1213 / Novo Nordisk
Phase classification, Trial completion date, Trial primary completion date: Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients (clinicaltrials.gov) - Oct 4, 2018
P2, N=90, Recruiting, Sponsor: University of California, Davis
Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Mar 2019 | Trial primary completion date: Dec 2018 --> Mar 2019 Phase classification: P=N/A --> P2 | Trial completion date: Jun 2026 --> Mar 2020 | Trial primary completion date: Jun 2026 --> Sep 2019
- | lenalidomide / Generic mfg.
Trial primary completion date: Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Oct 3, 2018
P2, N=48, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Phase classification: P=N/A --> P2 | Trial completion date: Jun 2026 --> Mar 2020 | Trial primary completion date: Jun 2026 --> Sep 2019 Trial primary completion date: Jul 2016 --> Jul 2020
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Enrollment closed: ROVE: Effect of Obesity on Immune Response to Pneumovax 23 (clinicaltrials.gov) - Sep 28, 2018
P=N/A, N=56, Active, not recruiting, Sponsor: University of Florida
Trial primary completion date: Jul 2016 --> Jul 2020 Recruiting --> Active, not recruiting
- | Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
Enrollment open: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM) (clinicaltrials.gov) - Sep 24, 2018
P3, N=250, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
Enrollment open: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX (clinicaltrials.gov) - Jul 23, 2018
P3, N=1500, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Entyvio (vedolizumab) / Takeda
Trial completion date, Trial primary completion date: Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab (clinicaltrials.gov) - Jul 13, 2018
P=N/A, N=400, Recruiting, Sponsor: Boston Medical Center
Not yet recruiting --> Recruiting Trial completion date: Jun 2018 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Dec 2019
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
Enrollment open: PNEU-WAY: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX (clinicaltrials.gov) - Jul 13, 2018
P3, N=300, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Jun 2018 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Dec 2019 Not yet recruiting --> Recruiting
- |||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
Enrollment open: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX (clinicaltrials.gov) - Jul 2, 2018
P3, N=600, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
New P3 trial: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM) (clinicaltrials.gov) - Jun 20, 2018
P3, N=250, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Phase classification, IO biomarker, Pneumococcal vaccines: Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults (clinicaltrials.gov) - Jun 18, 2018
P1, N=160, Recruiting, Sponsor: Medical University of South Carolina
Not yet recruiting --> Recruiting Phase classification: P=N/A --> P1
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Trial completion date, Trial primary completion date: ROVE: Effect of Obesity on Immune Response to Pneumovax 23 (clinicaltrials.gov) - Jun 15, 2018
P=N/A, N=56, Recruiting, Sponsor: University of Florida
Phase classification: P=N/A --> P1 Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2018 --> Jun 2019
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), NN1213 / Novo Nordisk
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Pneumococcal vaccines: Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses (clinicaltrials.gov) - Jun 8, 2018
P=N/A, N=60, Active, not recruiting, Sponsor: University of Colorado, Denver
Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2018 --> Jun 2019 Recruiting --> Active, not recruiting | N=120 --> 60 | Trial completion date: Mar 2018 --> Jun 2019 | Trial primary completion date: Feb 2018 --> Jun 2018
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
New P3 trial: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX (clinicaltrials.gov) - Jun 5, 2018
P3, N=1500, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Trial completion date, Trial primary completion date: ROVE: Effect of Obesity on Immune Response to Pneumovax 23 (clinicaltrials.gov) - Jun 4, 2018
P=N/A, N=56, Recruiting, Sponsor: University of Florida
Recruiting --> Active, not recruiting | N=120 --> 60 | Trial completion date: Mar 2018 --> Jun 2019 | Trial primary completion date: Feb 2018 --> Jun 2018 Trial completion date: May 2018 --> Dec 2018 | Trial primary completion date: May 2018 --> Dec 2018
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients (clinicaltrials.gov) - May 3, 2018
P=N/A, N=90, Recruiting, Sponsor: University of California, Davis
Trial completion date: May 2018 --> Dec 2018 | Trial primary completion date: May 2018 --> Dec 2018 Trial completion date: Apr 2018 --> Jun 2026 | Trial primary completion date: Apr 2018 --> Jun 2026
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
New P2 trial: ACQUIVAS: Acquired Immunodeficiency in ANCA Associated Vasculitis (clinicaltrials.gov) - May 2, 2018
P2, N=124, Not yet recruiting, Sponsor: Cambridge University Hospitals NHS Foundation Trust
- | Rabavert (purified chicken-embryo cell rabies vaccine) / Bavarian Nordic
Phase classification: Antibody Production in Immune Disorders (clinicaltrials.gov) - Mar 30, 2018
P, N=50, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial completion date: Apr 2018 --> Jun 2026 | Trial primary completion date: Apr 2018 --> Jun 2026 Phase classification: P=N/A --> P
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
New P3 trial: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX (clinicaltrials.gov) - Mar 29, 2018
P3, N=600, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
New P3 trial: PNEU-WAY: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX (clinicaltrials.gov) - Mar 29, 2018
P3, N=300, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- | Rituxan (rituximab) / Roche
Enrollment open, Pneumococcal vaccines: PNEUMOVAS: Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy (clinicaltrials.gov) - Mar 19, 2018
P2, N=120, Recruiting, Sponsor: Assistance Publique - H
Phase classification: P=N/A --> P Not yet recruiting --> Recruiting
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
New P1 trial: Dynamics of the Immune Response in Children to the 23-valent Pneumococcal Capsular Polysaccharide Vaccine (Pneumovax) (clinicaltrials.gov) - Mar 9, 2018
P1, N=100, Completed, Sponsor: KEMRI-Wellcome Trust Collaborative Research Program
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Pentacel (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and hemophilus b conjugate) / Sanofi, PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Trial completion date, Trial primary completion date: Vaccinating Children After Chemotherapy (clinicaltrials.gov) - Feb 22, 2018
P4, N=200, Recruiting, Sponsor: Dalhousie University
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2017 --> Dec 2018 | Trial completion date: Dec 2018 --> Dec 2019
- lenalidomide / Generic mfg.
Trial primary completion date: Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Jan 16, 2018
P2, N=3, Terminated, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2017 --> Dec 2018 | Trial completion date: Dec 2018 --> Dec 2019 Trial primary completion date: Nov 2018 --> Feb 2017
- ||| PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Enrollment change: Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age (clinicaltrials.gov) - Jan 5, 2018
P2, N=340, Active, not recruiting, Sponsor: Pfizer
Trial primary completion date: Nov 2018 --> Feb 2017 N=18 --> 340
- | PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
New P2 trial: Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age (clinicaltrials.gov) - Dec 19, 2017
P2, N=18, Active, not recruiting, Sponsor: Pfizer
- | PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Enrollment closed, Enrollment change: Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age (clinicaltrials.gov) - Dec 18, 2017
P2, N=18, Active, not recruiting, Sponsor: Pfizer
N=18 --> 340 Recruiting --> Active, not recruiting | N=440 --> 18 | Recruiting --> Active, not recruiting | N=440 --> 18 | Recruiting --> Active, not recruiting | N=440 --> 18
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Trial completion, Trial primary completion date: Systems Biology of PNEUMOVAX (clinicaltrials.gov) - Dec 13, 2017
P=N/A, N=88, Completed, Sponsor: Emory University
Recruiting --> Active, not recruiting | N=440 --> 18 | Recruiting --> Active, not recruiting | N=440 --> 18 | Recruiting --> Active, not recruiting | N=440 --> 18 Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Jul 2017
- | Rituxan (rituximab) / Roche
Trial initiation date, Trial primary completion date, Pneumococcal vaccines: PNEUMOVAS: Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy (clinicaltrials.gov) - Nov 9, 2017
P2, N=120, Not yet recruiting, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Jul 2017 Initiation date: May 2017 --> Dec 2017 | Trial primary completion date: Nov 2020 --> Jun 2021
- ||||| PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Clinical: Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age (clinicaltrials.gov) - Oct 18, 2017
P2, N=440, Recruiting, Sponsor: Pfizer
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Trial completion, Enrollment change: Immune Response to Pneumococcal Polysaccharide Vaccine (23-valent) Predicts Asthma Status and Outcomes in Late Adolescents With Asthma (clinicaltrials.gov) - Oct 11, 2017
P1, N=60, Completed, Sponsor: Rohit Divekar
Initiation date: May 2017 --> Dec 2017 | Trial primary completion date: Nov 2020 --> Jun 2021 Active, not recruiting --> Completed | N=260 --> 60
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Enrollment open, Pneumococcal vaccines: Pneumococcal Vaccines in Patients With Asthma (clinicaltrials.gov) - Oct 10, 2017
P4, N=50, Recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed | N=260 --> 60 Not yet recruiting --> Recruiting
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Enrollment open, IO biomarker, Pneumococcal vaccines: Sequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody Levels (clinicaltrials.gov) - Oct 6, 2017
P4, N=132, Recruiting, Sponsor: Jena University Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Trial completion, Trial primary completion date: SOT13: Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Compared to the Pneumococcal Polysaccharide Vaccine in Adult Kidney and Liver Transplant Patients (clinicaltrials.gov) - Oct 5, 2017
P4, N=182, Completed, Sponsor: Helsinki University Central Hospital
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Oct 2017
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Enrollment closed: Immune Response to Pneumococcal Polysaccharide Vaccine (23-valent) Predicts Asthma Status and Outcomes in Late Adolescents With Asthma (clinicaltrials.gov) - Aug 29, 2017
P1, N=260, Active, not recruiting, Sponsor: Rohit Divekar
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Oct 2017 Recruiting --> Active, not recruiting
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
New P4 trial, Pneumococcal vaccines: Pneumococcal Vaccines in Patients With Asthma (clinicaltrials.gov) - Aug 23, 2017
P4, N=50, Not yet recruiting, Sponsor: Mayo Clinic
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Trial initiation date, Trial primary completion date, IO biomarker, Pneumococcal vaccines: Sequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody Levels (clinicaltrials.gov) - Aug 18, 2017
P4, N=132, Not yet recruiting, Sponsor: Jena University Hospital
Recruiting --> Active, not recruiting Initiation date: Mar 2017 --> Sep 2017 | Trial primary completion date: Feb 2020 --> Aug 2020
- | Entyvio (vedolizumab) / Takeda
Enrollment open: Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab (clinicaltrials.gov) - Jul 11, 2017
P=N/A, N=400, Recruiting, Sponsor: Boston Medical Center
Initiation date: Mar 2017 --> Sep 2017 | Trial primary completion date: Feb 2020 --> Aug 2020 Not yet recruiting --> Recruiting